<DOC>
	<DOC>NCT01491932</DOC>
	<brief_summary>This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).</brief_summary>
	<brief_title>Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients who have completed a previous AFQ056A study or are eligible as defined in the core study protocol Outpatients Patients who have a primary caregiver willing and able to assess the condition of the patient throughout the study in accordance with protocol requirements Atypical or secondary form of Parkinson's disease History of surgical treatment for PD including deep brain stimulation Advanced, severe, or unstable disease (other than PD) History of malignancy Evidence of dementia Untreated/ineffectively treated mental disorders Treatment with certain prohibited medications Abnormal lab values or heart abnormalities Pregnant or nursing women</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>